Oncoinvent, BerGenBio merger set to complete by early November

The merger between BerGenBio ASA and Oncoinvent ASA is anticipated to complete on October 29, 2025. Key dates include the last day of trading for Oncoinvent on Euronext Growth Oslo on October 29, and the first day of trading for the combined entity on the Oslo Stock Exchange on October 30. The record date for consideration shares is October 31, with delivery to former Oncoinvent shareholders by November 3.

BerGenBio will change its company name to "Oncoinvent ASA" and retain the "ONCIN" ticker. Oncoinvent will change its ticker to "ONCOI" effective October 28. Oncoinvent shareholders will receive 1.202680493545220 BerGenBio shares for each Oncoinvent share held, rounded down to the nearest whole share.

The merger consideration involves issuing 117,554,012 new BerGenBio shares, increasing BerGenBio's total share capital to NOK 156,641,128, divided into 156,641,128 shares, each with a nominal value of NOK 1. A prospectus detailing further merger information is expected on October 28.

Oncoinvent, the transferor company, is a clinical-stage biotechnology firm specializing in radiopharmaceutical cancer therapies, with its lead candidate Radspherin currently in Phase 2 clinical trials across the US, UK, and Europe. BerGenBio Norge AS will be the transferee company.